Swedish Orphan Biovitrum AB (publ)
STO:SOBI

Watchlist Manager
Swedish Orphan Biovitrum AB (publ) Logo
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Watchlist
Price: 311.6 SEK 0.39% Market Closed
Market Cap: 107B SEK
Have any thoughts about
Swedish Orphan Biovitrum AB (publ)?
Write Note

Gross Margin
Swedish Orphan Biovitrum AB (publ)

78.6%
Current
77%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
78.6%
=
Gross Profit
20B
/
Revenue
25.4B

Gross Margin Across Competitors

Country SE
Market Cap 107.2B SEK
Gross Margin
79%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 310.2B USD
Gross Margin
67%
Country US
Market Cap 142B USD
Gross Margin
60%
Country US
Market Cap 115B USD
Gross Margin
78%
Country US
Market Cap 101.6B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 78.5B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Swedish Orphan Biovitrum AB (publ)
Glance View

Market Cap
107B SEK
Industry
Biotechnology

Swedish Orphan Biovitrum AB (publ), often known as Sobi, navigates the intricate world of biopharmaceuticals with a singular focus on developing and delivering innovative treatments for rare diseases. Founded in the heart of Scandinavia, Sobi has crafted a unique niche by addressing medical needs that are often overlooked by larger pharmaceutical companies. The company specializes in hematology and immunology, focusing on conditions where it can leverage its expertise to make a tangible difference. With a robust pipeline of biopharmaceutical products, Sobi dedicates itself to research and partnerships that not only drive scientific advancements but also ensure that its therapies reach the global market. This mission aligns with its deep commitment to patients whose conditions lack effective treatments. Sobi’s business model thrives on a blend of strategic acquisitions, rigorous clinical development, and expansive distribution capabilities. By acquiring promising therapies and collaborating with other innovators in the biotech space, it continually expands its product portfolio and market reach. Revenue flows primarily from the sales of these specialized therapies, which command premium pricing due to their targeted nature and the complex manufacturing processes involved. The company also invests significantly in its research and development programs, channeling insights from its interactions with healthcare professionals and patients to optimize its offerings. Through its relentless focus on rare diseases, Sobi not only secures financial returns but also significantly impacts the quality of life for patients, staying true to its foundational ethos.

SOBI Intrinsic Value
380.42 SEK
Undervaluation 18%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
78.6%
=
Gross Profit
20B
/
Revenue
25.4B
What is the Gross Margin of Swedish Orphan Biovitrum AB (publ)?

Based on Swedish Orphan Biovitrum AB (publ)'s most recent financial statements, the company has Gross Margin of 78.6%.